Bg pattern

VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Veklury 100 mg powder for concentrate for solution for infusion

remdesivir

This medicinal product is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or nurse.
  • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

If Veklury has been prescribed to your child, note that all the information in this leaflet is intended for your child (in this case, when you read “you” replace it with “your child”).

Contents of the pack

  1. What is Veklury and what is it used for
  2. What you need to know before you are given Veklury
  3. How Veklury is given
  4. Possible side effects
  5. Storage of Veklury
  6. Contents of the pack and other information

1. What is Veklury and what is it used for

The active substance of Veklury is remdesivir. It is an antiviral medicine used to treat COVID-19.

COVID-19 is caused by a virus called coronavirus. Veklury stops the virus from multiplying in the cells, and this stops the virus from multiplying in the body. This can help your body to overcome the viral infection and can help you to recover faster.

Veklury will be given to treat COVID-19 in:

  • adults and children from at least 4 weeks of age and who weigh at least 3 kg) who have pneumonia, and who need extra oxygen to help them breathe, but who are not receiving artificial ventilation (in which mechanical means are used to assist or replace spontaneous breathing).
  • adults and children (who weigh at least 40 kg) who do not need extra oxygen to help them breathe and who are at higher risk of developing severe COVID-19.
Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you are given Veklury

Veklury will not normally be given to you:

  • if you are allergicto remdesivir or any of the other ingredients of this medicine (listed in section 6).

Tell your doctor or nurse as soon as possible,if this applies to you.

Warnings and precautions

Tell your doctor or nurse before starting treatment with Veklury:

  • if you have kidney problems.Your doctor may monitor you if you have kidney problems to ensure your safety.
  • if you are immunocompromised.Your doctor may monitor you more closely if your immune system is not working properly to ensure that the treatment is working.

Infusion-related reactions

Veklury may cause allergic reactions during or after the infusion, including anaphylactic reactions (sudden, potentially life-threatening allergic reactions). Allergic reactions have been observed rarely. For anaphylactic reactions, the frequency cannot be estimated from the available data. The symptoms may be:

  • Changes in blood pressure or heart rate
  • Low oxygen level in the blood
  • High temperature
  • Shortness of breath, wheezing
  • Swelling of the face, lips, tongue, or throat (angioedema)
  • Rash
  • Nausea
  • Vomiting
  • Sweating
  • Chills

Tell your doctor or nurse immediatelyif you notice any of these effects.

Blood tests before and during treatment

If you have been prescribed Veklury, you may have blood tests before starting treatment. Patients who are being treated with Veklury may have blood tests during their treatment as determined by their healthcare professionals. These tests are to detect kidney problems.

Children and adolescents

Veklury must not be given to children under 4 weeks of age or to children who weigh less than 3 kg. Not enough is known for it to be given to these children.

Other medicines and Veklury

Tell your doctor or nurseif you are taking or have recently taken any other medicines.

Do not take chloroquine or hydroxychloroquine at the same time as Veklury.

Tell your doctor if you are taking any of these medicines

Pregnancy and breast-feeding

Tell your doctor or nurse if you are pregnantor if you think you might be pregnant. There is not enough information to confirm that Veklury is safe to use in the first trimester of pregnancy. Veklury should only be given if the potential benefits of treatment outweigh the potential risks to the mother and the fetus. Talk to your doctor about the need to use effective contraceptive methods during treatment with Veklury.

Tell your doctor or nurse if you are breast-feeding.Veklury passes into breast milk in very small amounts. Because experience with use during breast-feeding is limited, you should discuss with your doctor whether you should continue or stop breast-feeding during treatment with Veklury.

Driving and using machines

Veklury is not expected to have any effect on the ability to drive.

Veklury contains a cyclodextrin

This medicine contains 3 g of betadex sulfobutyl ether sodium in each 100 mg dose of Veklury (6 g in the initial dose). This component is a cyclodextrin excipientthat helps the medicine to disperse in the body.

Veklury contains sodium

This medicine contains 212 mg of sodium (the main component of cooking/table salt) in each 100 mg dose. This is equivalent to 10.6% of the maximum recommended daily intake of sodium for an adult.

3. How Veklury is given

A nurse or doctor will give you Veklury through a drip into a vein (intravenous infusion) over 30 to 120 minutes, once a day. You will be closely monitored during treatment.

Recommended dose in adults and children

Adults

Children (who weigh at least 40 kg)

Children from at least 4 weeks of age (who weigh at least 3 kg, but less than 40 kg)

Day 1

(single initial dose)

200 mg

200 mg

5 mg per kg of body weight

From Day 2 onwards

(once daily)

100 mg

100 mg

2.5 mg per kg of body weight

per day

Duration of treatment

Adults

Children (who weigh at least 40 kg)

Children from at least 4 weeks of age (who weigh at least 3 kg, but less than 40 kg)

Patient with pneumonia

requiring supplemental

oxygen

Every day for at least

5 days.Treatment may be

extended up to a total of 10 days

Every day for at least

5 days.Treatment may be

extended up to a total of 10 days.

Every day for up to a total

of 10 days

Patient who do not

require supplemental

oxygenand are at

higher risk of developing

severe COVID-19

Every day for 3 days; treatment

should be started within 7 days

of the onset of COVID-19

symptoms.

Every day for 3 days; treatment

should be started within 7 days

of the onset of COVID-19

symptoms.

Not applicable

Refer to the Instructions for healthcare professionalswhich provide details on how to administer the Veklury infusion.

If you are given too much or too little Veklury

Because Veklury is given to you by a healthcare professional, it is unlikely that you will be given too much or too little. If you have been given an extra dose or missed a dose, tell your nurse or doctor immediately.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects may be serious:

Rare

(may affect up to 1 in 1,000 people)

  • Allergic reactions during or after the infusion. The symptoms may be:
  • Changes in blood pressure or heart rate
  • Low oxygen level in the blood
  • High temperature
  • Shortness of breath, wheezing
  • Swelling of the face, lips, tongue, or throat (angioedema)
  • Rash
  • Nausea
  • Vomiting
  • Sweating
  • Chills

Frequency not known

(frequency cannot be estimated from the available data)

  • Anaphylactic reactions, anaphylactic shock (sudden, potentially life-threatening allergic reactions)

The symptoms are the same as those of allergic reactions, however, the reaction is more severe and requires immediate medical attention.

  • Sinus bradycardia (the heart beats more slowly than normal)

Tell your doctor or nurse immediatelyif you notice any of these effects.

Other side effects:

Very common side effects

(may affect more than 1 in 10 people)

  • Blood tests may show an increase in liver enzymes, called transaminases
  • Blood tests may show that the blood takes longer to clot.

Common side effects

(may affect up to 1 in 10 people)

  • Headache
  • Nausea
  • Rash

Reporting of side effects

If you experience any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Veklury

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of the month shown.

  • Before use,this medicine does not require any special storage precautions.
  • After reconstitution,Veklury should be diluted immediately.
  • After dilution,Veklury should be used immediately. If necessary, the bags of diluted solution may be stored for up to 24 hours at a temperature below 25°C or up to 48 hours in a refrigerator. Do not exceed 48 hours between dilution and administration.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Package Contents and Additional Information

Veklury Composition

  • The active ingredientis remdesivir. Each vial contains 100 mg.
  • The other ingredientsare: betadex sulfobutyl ether sodium, hydrochloric acid, and sodium hydroxide.

Appearance of the Product and Package Contents

Veklury 100 mg powder for concentrate for solution for infusion is a powder of white, off-white, or yellow color that must be reconstituted and then diluted in a sodium chloride solution before administration by intravenous infusion. It is supplied in a single-use transparent glass vial.

Veklury is available in boxes containing 1 vial.

Marketing Authorization Holder and Manufacturer

Gilead Sciences Ireland UC

Carrigtohill

County Cork, T45 DP77

Ireland

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Belgium/Belgique/Belgien

Gilead Sciences Belgium SRL-BV

Tel: + 32 (0) 24 01 35 50

Lithuania

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Luxembourg/Luxemburg

Gilead Sciences Belgium SRL-BV

Tel: + 32 (0) 24 01 35 50

Czech Republic

Gilead Sciences s.r.o.

Tel: + 420 910 871 986

Hungary

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Denmark

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Malta

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Germany

Gilead Sciences GmbH

Tel: + 49 (0) 89 899890-0

Netherlands

Gilead Sciences Netherlands B.V.

Tel: + 31 (0) 20 718 36 98

Estonia

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Norway

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Greece

Gilead Sciences Ελλάς Μ.ΕΠΕ.

Tel: + 30 210 8930 100

Austria

Gilead Sciences GesmbH

Tel: + 43 1 260 830

Spain

Gilead Sciences, S.L.

Tel: + 34 91 378 98 30

Poland

Gilead Sciences Poland Sp. z o.o.

Tel: + 48 22 262 8702

France

Gilead Sciences

Tel: + 33 (0) 1 46 09 41 00

Portugal

Gilead Sciences, Lda.

Tel: + 351 21 7928790

Croatia

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Romania

Gilead Sciences (GSR) S.R.L.

Tel: + 40 31 631 18 00

Ireland

Gilead Sciences Ireland UC

Tel: + 353 (0) 214 825 999

Slovenia

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

Iceland

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Slovakia

Gilead Sciences Slovakia s.r.o.

Tel: + 421 232 121 210

Italy

Gilead Sciences S.r.l.

Tel: + 39 02 439201

Finland

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Cyprus

Gilead Sciences Ελλάς Μ.ΕΠΕ.

Tel: + 30 210 8930 100

Sweden

Gilead Sciences Sweden AB

Tel: + 46 (0) 8 5057 1849

Latvia

Gilead Sciences Ireland UC

Tel: + 353 (0) 1 686 1888

United Kingdom (Northern Ireland)

Gilead Sciences Ireland UC

Tel: + 44 (0) 8000 113 700

Date of Last Revision of this Leaflet: .

Other Sources of Information

Scan the code below with a mobile device to obtain this information in different languages.

QR code to be included www.veklury.eu

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.

The European Medicines Agency website can be found in all languages of the European Union/European Economic Area.

---------------------------------------------------------------------------------------------------------------------------

The following information is intended for healthcare professionals only.

For more information, consult the Summary of Product Characteristics.

Instructions for Healthcare Professionals

Veklury 100 mg Powder for Concentrate for Solution for Infusion

remdesivir

Each single-use vial contains 100 mg of remdesivir as a white, off-white, or yellow powder for reconstitution and dilution.

Treatment Summary

Veklury is used for the treatment of COVID-19 in:

  • adult and pediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia who require supplemental oxygen (high or low flow oxygen or other non-invasive ventilation at the start of treatment).
  • adult and pediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and are at higher risk of progressing to severe COVID-19.

Veklury should be administered by intravenous infusion in a total volume of 25 ml, 50 ml, 100 ml, or 250 ml of sodium chloride 0.9% solution over 30 to 120 minutes.

Table 1:

Recommended Dose in Adult and Pediatric Patients

Adults

Pediatric Patients (weighing at least 40 kg)

Pediatric Patients at least 4 weeks of age (weighing at least 3 kg but less than 40 kg)

Day 1

(single loading dose)

200 mg

200 mg

5 mg/kg

From Day 2 onwards

(once daily)

100 mg

100 mg

2.5 mg/kg

Table 2:

Duration of Treatment

Adults

Pediatric Patients (weighing at least 40 kg)

Pediatric Patients at least 4 weeks of age (weighing at least 3 kg but less than 40 kg)

Patient with pneumonia

requiring supplemental oxygen

Every day for at least 5 daysand no more than 10 days.

Every day for at least 5 daysand no more than 10 days.

Every day for up to a total of 10 days.

Patient who do not require

supplemental oxygenand

are at higher risk of

progressing to severe COVID-19

Every day for 3 days; treatment should be initiated as soon as possible after diagnosis of COVID-19 and within 7 days of symptom onset.

Every day for 3 days; treatment should be initiated as soon as possible after diagnosis of COVID-19 and within 7 days of symptom onset.

Not applicable.

The powder should be reconstituted with sterile water for injection and then diluted in sodium chloride 9 mg/ml (0.9%) solution under aseptic conditions. Administer the diluted solution immediately.

As clinically appropriate, renal function should be determined in patients before starting treatment with remdesivir and while receiving it.

Monitor the patient for adverse effects during and after infusion. See below for details on adverse effect reporting.

Reconstituting the Powder

For each single-use vial, the powder should be reconstituted and then diluted under aseptic conditions.

  • Add 19 ml of sterile water for injection to the vial, using a syringe and needle of suitable size for each vial, and insert the needle into the center of the vial stopper.
  • This produces a solution of 5 mg/ml of remdesivir.
  • Discard the vial if the vacuum does not draw the sterile water into the vial.
  • Use only sterile water for injectionto reconstitute remdesivir powder.
  • Shake the vial immediately for 30 seconds.
  • Allow the vial contents to settle for 2 to 3 minutes. A clear solution should form.
  • If the vial contents have not dissolved completely, shake the vial again for 30 seconds and allow the contents to settle for 2 to 3 minutes. Repeat this procedure as necessary until the vial contents have dissolved completely.
  • Inspect the vial to ensure the container closure is not defective.
  • The solution should only be used if it is clear and free of particles.
  • Dilute immediately after reconstitution.

Diluting the Concentrate with Sodium Chloride Solution

Reconstituted Veklury should be diluted in sodium chloride 9 mg/ml (0.9%) solution for injection under aseptic conditions.

Dilution Instructions for Adult and Pediatric Patients Weighing at Least 40 kg

Using Table 3, determine the volume of sodium chloride 9 mg/ml (0.9%) solution to withdraw from the infusion bag.

Table 3:

Dilution Instructions

Dose

Infusion Bag Size to Use

Volume of Sodium Chloride Solution to Withdraw and Discard from Infusion Bag

Volume of Reconstituted Veklury

200 mg (2 vials)

250 ml

40 ml

2 × 20 ml

100 mg (1 vial)

250 ml

20 ml

20 ml

100 ml

20 ml

20 ml

Note: The 100 ml infusion should only be used in patients with severe fluid restrictions.

  • Withdraw and discard the required volume of sodium chloride solution from the infusion bag using a syringe and needle of suitable size. See Table 3.
  • Withdraw the required volume of reconstituted Veklury from the vial using a syringe of suitable size. See Table 3.
  • Transfer the reconstituted Veklury to the infusion bag.
  • Gently invert the bag 20 times to mix the solution in the bag. Do not shake.
  • Administer the diluted solution immediately or as soon as possible after preparation. The diluted solution is stable for 24 hours at room temperature (between 20°C and 25°C) or for 48 hours in the refrigerator (between 2°C and 8°C).

Dilution Instructions for Pediatric Patients at Least 4 Weeks of Age and Weighing at Least 3 kg but Less Than 40 kg

  • Dilute the remdesivir 100 mg/20 ml (5 mg/ml) concentrate further using sodium chloride 0.9% to achieve a fixed concentration of 1.25 mg/ml.
  • The total infusion volume of remdesivir 1.25 mg/ml solution for infusion is calculated based on the pediatric dosing guidelines based on weight of 5 mg/kg for the loading dose and 2.5 mg/kg for each maintenance dose.
  • Small sodium chloride 0.9% infusion bags (e.g., 25, 50, or 100 ml) or a syringe of suitable size should be used to administer the dose to pediatric patients. The recommended dose is administered by intravenous infusion in a total volume dependent on the dose to achieve the target remdesivir concentration of 1.25 mg/ml.
  • A syringe may be used for administration of volumes < 50 ml.

Administering the Infusion

  • It is possible to use in cases of severe hypersensitivity reactions, such as anaphylaxis.
  • Administer the diluted solution over 30 to 120 minutes at the rate described in Table 4 or Table 5.
  • Once the infusion is complete, flush with at least 30 ml of sodium chloride 9 mg/ml (0.9%) solution.
  • The diluted solution should not be administered simultaneously with any other medication in the same intravenous line. The compatibility of Veklury with other IV solutions and medications is unknown.

Table 4:

Infusion Rate in Adult and Pediatric Patients Weighing 40 kg or More

Infusion Bag Volume

Infusion Time

Infusion Rate

250 ml

30 min

8.33 ml/min

60 min

4.17 ml/min

120 min

2.08 ml/min

100 ml

30 min

3.33 ml/min

60 min

1.67 ml/min

120 min

0.83 ml/min

Table 5:

Infusion Rate in Pediatric Patients at Least 4 Weeks of Age and Weighing at Least 3 kg but Less Than 40 kg

Infusion Bag Volume

Infusion Time

Infusion Rate

100 ml

30 min

3.33 ml/min

60 min

1.67 ml/min

120 min

0.83 ml/min

50 ml

30 min

1.67 ml/min

60 min

0.83 ml/min

120 min

0.42 ml/min

25 ml

30 min

0.83 ml/min

60 min

0.42 ml/min

120 min

0.21 ml/min

a The infusion rate can be adjusted based on the total volume to be infused.

Monitoring and Reporting of Adverse Effects

  • Monitor the patient for adverse effects during and after infusion according to local medical practice.
  • Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Safe Storage of Veklury

  • Before use,this medicinal product does not require any special storage precautions. Do not use after the expiry date stated on the vials/cartons after the letters EXP.
  • Veklury powder is white, off-white, or yellow. The color does not affect the stability of the product.
  • After reconstitution,Veklury should be diluted immediately.
  • After dilution,Veklury should be administered immediately. If necessary, the diluted solution bags can be stored for up to 24 hours at room temperature (between 20°C and 25°C) or up to 48 hours in the refrigerator (between 2°C and 8°C). Do not exceed 48 hours between dilution and administration.

Do not reuse or store unused Veklury powder, reconstituted solution, or diluted solution.

Information in Other Languages

  • Scan the code below with a mobile device to obtain information in different languages.

QR code to be included www.veklury.eu

Date of last revision of this leaflet: .

Online doctors for VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

Discuss questions about VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (25)
Doctor

Lina Travkina

Family medicine 13 years exp.

Dr. Lina Travkina is a licensed family and preventive medicine doctor based in Italy. She provides online consultations for adults and children, supporting patients across all stages of care – from acute symptom management to long-term health monitoring and prevention.

Areas of medical care include:

  • Respiratory conditions: colds, flu, acute and chronic bronchitis, mild to moderate pneumonia, bronchial asthma.
  • ENT and eye conditions: sinusitis, tonsillitis, pharyngitis, otitis, infectious and allergic conjunctivitis.
  • Digestive issues: gastritis, acid reflux (GERD), IBS, dyspepsia, bloating, constipation, diarrhoea, functional bowel symptoms, intestinal infections.
  • Urological and infectious diseases: acute and recurrent cystitis, bladder and kidney infections, prevention of recurrent UTIs, asymptomatic bacteriuria.
  • Chronic conditions: hypertension, diabetes, hypercholesterolemia, metabolic syndrome, thyroid disorders, excess weight.
  • Neurological and general symptoms: headache, migraine, dizziness, fatigue, sleep disturbances, reduced concentration, anxiety, asthenia.
  • Chronic pain support: back, neck, joint, and muscle pain, tension syndromes, pain associated with osteochondrosis and chronic conditions.

Additional care areas:

  • Preventive consultations and check-up planning.
  • Medical advice and follow-up consultations.
  • Test interpretation and diagnostic guidance.
  • Structured support for undiagnosed complaints.
  • Second opinion on diagnoses and treatment plans.
  • Nutritional and lifestyle support for vitamin deficiencies, anaemia, metabolic issues.
  • Post-operative recovery support and pain management.
  • Preconception counselling and postpartum support.
  • Immunity support and strategies to reduce frequency of infections.

Dr. Travkina combines evidence-based medicine with an attentive, personalised approach. Her consultations focus not only on treatment, but also on prevention, recovery, and long-term wellbeing.

If during the consultation it becomes clear that your case requires in-person assessment or specialised care outside of her scope, the session will be terminated and the payment fully refunded.

Camera Book a video appointment
€70
5.0 (760)
Doctor

Alina Tsurkan

Family medicine 13 years exp.

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including:

  • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs.
  • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis.
  • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation.
  • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea.
  • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections.
  • Chronic diseases: hypertension, elevated cholesterol, weight management.
  • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness.
  • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance.

She also provides:

  • IMT medical certificates for driving licence exchange in Portugal.
  • Personalised preventive care and wellness consultations.
  • Interpretation of test results and medical reports.
  • Follow-up care and medication review.
  • Support in managing multiple coexisting conditions.
  • Remote prescription management and medical documentation.

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

Camera Book a video appointment
€55
5.0 (140)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50

Frequently Asked Questions

Is a prescription required for VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION?
VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION?
The active ingredient in VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION is remdesivir. This information helps identify medicines with the same composition but different brand names.
Who manufactures VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION?
VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION is manufactured by Gilead Sciences Ireland Unlimited Company. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to VEKLURY 100 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION?
Other medicines with the same active substance (remdesivir) include ACICLOVIR ACCORD 25 mg/ml CONCENTRATE FOR INFUSION SOLUTION, ACICLOVIR ACCORD 250 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION, ACICLOVIR ALTAN 250 mg POWDER FOR SOLUTION FOR INFUSION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media